20Jan 2017

METABOLIC SYNDROME AND ELEVATEDOSTEOPONTIN: THEIR ASSOCIATED COMORBIDITIES IN PATIENTS WITH PSORIASIS.

  • Department of Internal Medicine. Faculty of Medicine, Zagazig University, Egypt.
  • Department of Dermatology.Faculty of Medicine, Zagazig University, Egypt.
  • Department of Clinical pathology, Faculty of Medicine, Zagazig University, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background:Psoriasis is a systemic, chronic, and hyper-proliferative immune mediated skin disorder.Osteopontin influences cell mediated immunity and plays an important role during both acute and chronic inflammation. We aimed to assess metabolic syndrome and osteopontin and their associated systemic comorbidities in patients with psoriasis. Subjects and methods: The study included 48 subjects: 24 patients of psoriasis of any age, both sexes with different grades of disease severity. Severity was assessed by psoriasis area and severity index (PASI) score, .Their mean age was (33.25±12.9),13 of them were females (54.2%) and 11 were males (45.8%). In addition to 24 healthy control group, 15 females (62.5%) and 9 males (37.5%). Their mean age was (31.63 ± 16.52). Clinical, demographic evaluation and dermatological examination of the psoriatic lesions (site of the lesion, morphology and progression of the disease and severity ) was performed in addition to serological testing of serum OPN level, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, and fasting blood glucose(FBG). Results:psoriatic cases showed,elevatedbody mass index,FBG , serum osteopontin, cholesterol, triglycerides and low density lipoprotein cholesterol and decreased levels of high density lipoprotein cholesterol than normal control.Metabolic syndrome and hypertension representing 25% and 41.6% respectively of psoriatic cases.In psoriatic cases, psoriasis area and severity index (PASI) score, had significant positive correlation with obesity,blood pressure, FBG, dyslipidemia,but no correlation with age, disease duration.Serum OPN had positive correlation with age,blood pressure but no correlation with BMI, disease duration, FBS ordyslipidemia. Conclusions Psoriatic patients have a high prevalence of metabolic syndrome . High level of OPN can be used as an early detector of cardiovascular problems in psoriatic patients and this inflammatory cytokine can be used as a new target in the treatment of psoriasis.

  1. Mahajan R and Handa S (2013) : Pathophysiology of psoriasis. Indian. J DermatolVenereolLeprol ; 79:1-9.
  2. Abdelnoor AM and Al-Akl N (2013): Factors Involved in the Pathogenesis of psoriasis. Adv S Med Scien ;1(2): 75-94.
  3. VM Voiculescu, M Lupu, L Papagheorghe,C Giurcaneanu, and E Micu(2014):Psoriasis and Metabolic Syndrome – scientific evidence and therapeutic implications,J Med Life. 2014 Oct-Dec; 7(4): 468–471.
  4. Bassyouni IH, Bassyouni RH, Ibrahim NH, et al (2012) :Elevated Serum Osteopontin Levels in Chronic Hepatitis C Virus Infection:Association with Autoimmune Rheumatologic Manifestations. J ClinImmunol ; 32:1262–1269.
  5. Sase S P, Nagane N., Ganu J V. Osteopontin: A Novel Protein Molecule. Indian Medical Gazette. 2012 Feb ; 145 (2): 62-66.
  6. Cheng X, Yu X, Ding YJ, et al (2008) : The Th17/Treg imbalance in patients with acute coronary syndrome. ClinImmunol2008 ; 127: 89–97.
  7. Mazzone A, Parri MS, Giannessi D, et al (2011): Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study. J Coron Artery Dis ; 22(3):179-187.
  8. Alain-P G.,Hervé C.,DanièleD.,Mark K et al (2001):Time Course of Osteopontin, Osteocalcin, and Osteonectin Accumulation and Calcification After Acute Vessel Wall Injury, J HistochemCytochem January 2001 vol. 49 no. 1 79-86
  9. Mattei PL1, Corey KC, Kimball AB.(2013):Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.J EurAcadDermatolVenereol. 2014 Mar;28(3):333-7. . Epub 2013 Feb 21.
  10. Langley RG and Ellis CN (2004) : Evaluating psoriasis with Psoriasis area and Severity Index, Psoriasis Global Assessment and Lattice System Physician Global Assessment. J Am AcadDermatol ; 51:563-569.
  11. K?l?ç A and Cakmak S (2013) :Psoriasis and comorbidities. EMJ Dermatol ; 1:78-85.
  12. Lima H, Dogan S, Atakan N, et al (2013) : Psoriasis, types, causes and medications. InTech ; 51(1):978-953.
  13. Lowes MA,Suárez-Fariñas M and Krueger JG (2014) : Immunology of Psoriasis. J Annu Rev Immunol; 32:227-255.
  14. Kahles F, Findeisen H M and Bruemme D (2014): Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes .J MolMetab ; 3(6):384-393.
  15. Buback F, Renkl  AC, Schulz G, et al (2009): Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. J ExpDermatol ; 18:750–759.
  16. Buommino E, Filippis A, Gaudiello F, et al (2012): Modification of osteopontin and MMP-9 levels in patients with psoriasis on anti-TNF? therapy. Arch Dermatol Res; 304(6):481-5.
  17. Balta I, Balta S, Demirkol S, et al (2013): Other inflammatory markers and related factors should be kept in mind in metabolic syndrome with psoriasis patients. Arch DermatolRes ; 305:459–460 .
  18. Armstrong AW, Harskamp CT, Armstrong EJ (2013): Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am AcadDermatol ; 68:654–662.
  19. Nakajima H, Nakajima K, Tarutani M, Sano S (2012) The role of pigment epithelium-derived factor as an adipokine in psoriasis. Arch Dermatol Res 304(1):81–84
  20. Boehncke W., Boehncke S., Tobin A., Kirby B. (2011)The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. ExpDermatol 20: 303–307
  21. Albareda M, Ravella A, Castelló M et al (2014):Metabolic syndrome and its components in patients with psoriasis.Springer plus;3:612.
  22. Joshi R. (2004):Immunopathogenesis of psoriasis. Indian J DermatolVenereolLeprol; 70:10-2.
  23. Farshichian M, Zamanian A, Farshichian M, et al (2007) :Serum lipid levels in Iranian patients withpsoriasis. J EurAssocDermatolVenereol; 21: 802–805.
  24. ,Dahlia W.,BaytaD.,JonathanS.,et al (2008):Ssoriasis and Dyslipidaemia:APopulatio – based study,ActaDermVenereol 2008;88:561-565
  25. Strober BE, Poulin Y, Kerdel FA, et al (2011): Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am AcadDermatol; 664:671.
  26. Karadag AS, Yavuz B, Ertugrul DT, et al (2010): Is psoriasis a preatherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol;48(6):642–646.
  27. Escarcega RO, Garcia-Carrasco M, Fuentes-Alexandro S, et al (2006): Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmune Rev; 6:48-53.
  28. Rocha-Preira P, Santos-Silva A, Rebelo I, et al (2001): Dyslipdemia and oxidative stress inmild and in severe psoriasis as a risk for cardiovascular disease.ClinChimActa; 303:33-90.
  29. WakkeeM,ThioHB,Prens EP, et al(2007): Unfavorable cardiovascular risk profiles in untreated andtreated psoriasis patients. Atherosclerosis; 190: 1–9.
  30. Lotus Mallbris, MD, PhD ,FredrikGranath, Anders Hamsten,ET AL (2006):Psoriasis is associated with lipid abnormalities at the onset of skin disease,JAAD,April 2006Volume 54, Issue 4, Pages 614–621
  31. Robati RM1, Partovi-Kia M1, Sadat-Amini H1, Haghighatkhah HR2, et al (2016): Serum osteopontin level and common carotid artery intima-media wall thickness in psoriasis. Int J Dermatol. 2016 May;55(5):e262-7. Epub 2016 Jan 15.
  32. Toossi P1, Sadat Amini SH1, Sadat Amini MS2, Partovi Kia M1, et al(2015):Assessment of serum levels of osteopontin, selenium and prolactin in patients with psoriasis compared with healthy controls, and their association with psoriasis severity.ClinExpDermatol. 2015 Oct;40(7):741-6. doi: 10.1111/ced.12657. Epub 2015 May 19.
  33. Amin MM and Azim ZA (2012): Immunohistochemical study of osteopontin, Ki-67 and CD34 of psoriasis in Mansoura , Egypt. Indian J PatholMicrobiol ; 55(1):56–60.
  34. El-Eishi NH, Kadry D, Hegazy RA, Rashed L (2012) : Estimation of tissue osteopontin levels before and after different traditional therapeutic modalities in psoriatic patients. J EurAcadDermatol Venereol;27(3):351-5.
  35. Gaspari AA (2006): Innate and adaptive immunity and the pathophy-siology of psoriasis .J Am AcadDermatol ; 54(3suppl2):67-80.
  36. Giachelli CM and Steitz (2000) :S.Osteopontin: A Versatile regulator of inflammation and biomineralization. J Matrix Biol ; 19(7):615-622.
  37. Nissinen L and Kähäri VM (2014): Matrix metalloproteinases in inflammation . J BiochimBiophysActa; 1840(8):2571-2580.
  38. Abdel-Azeez HA and Al-Zaky M (2010): Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal ;24(3):201-206.

[Hoda G. Bakr, Fatma Eldesouky, Abdallah H kandil and Samar M. Sharaf. (2017); METABOLIC SYNDROME AND ELEVATEDOSTEOPONTIN: THEIR ASSOCIATED COMORBIDITIES IN PATIENTS WITH PSORIASIS. Int. J. of Adv. Res. 5 (Jan). 1535-1546] (ISSN 2320-5407). www.journalijar.com

Hoda G. Bakr
assistant prof . of internal medicine .Zagazig university hospital . Egypt

DOI:

Article DOI: 10.21474/IJAR01/2918      
DOI URL: https://dx.doi.org/10.21474/IJAR01/2918

Download Full Paper

Download PDF No. of Downloads: 15 | No. of Views: 77